Search
SLCO1B1/SLC21A6 genotyping
Indications:
- risk assessment for adverse drug effects of hepatically cleared drugs (SLCO1B1 gene variant affecting hepatic clearance)
- statin-induced myopathy (simvastatin)
- methotrexate therapy
Related
SLCO1B1 gene variant affecting hepatic clearance
solute carrier family 21 member 6; solute carrier organic anion transporter family member 1B1; liver-specific organic anion transporter 1; LST-1; OATP-C; Na+-independent organic anion-transporting polypeptide 2; OATP-2 (SLCO1B1, LST1, OATP1B1, OATP2, OATPC, SLC21A6)
General
genotyping (allele testing)
References
- Link E et al.
SLCO1B1 variants and statin-induced myopathy.
A genomewide study.
N Engl J Med 2008 Aug 21; 359:789.
PMID: 18650507
http://dx.doi.org/10.1056/NEJMoa0801936
- Ramsey LB, Johnson SG, Caudle KE et al
The Clinical Pharmacogenetics Implementation Consortium
guideline for SLCO1B1 and simvastatin-induced myopathy: 2014
update.
Clin Pharmacol Ther. 2014 Oct;96(4):423-8
PMID: 24918167